Literature DB >> 11425367

Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions.

A Bartolazzi1, A Gasbarri, M Papotti, G Bussolati, T Lucante, A Khan, H Inohara, F Marandino, F Orlandi, F Nardi, A Vecchione, R Tecce, O Larsson.   

Abstract

BACKGROUND: Thyroid cancer is the most common endocrine malignant disease, but preoperative diagnosis remains a challenge. Fine-needle aspiration cytology has greatly improved the clinical management of thyroid nodules, but the preoperative characterisation of follicular lesions is very difficult. Many patients are thus referred to surgery more for diagnosis than for therapeutic necessity. We undertook an international multicentre study to assess the usefulness of immunohistocytochemical staining for two potential markers of malignant thyrocytes.
METHODS: Expression of galectin-3 and CD44v6 was tested on 1009 thyroid lesions (tissue specimens and cytological cell-blocks) and 226 fresh cytological samples obtained preoperatively by ultrasound-guided fine-needle aspiration of thyroid nodules (prospective analysis). The test used monoclonal antibodies specific for CD44v6 and galectin-3, the indirect avidin-biotin complex immunoperoxidase method, and 3-amino-9-ethyl-carbazole as substrate.
FINDINGS: The sensitivity, specificity, positive predictive value, and diagnostic accuracy of this test method (for coexpression of the two markers) in the prospective analysis were 88%, 98%, 91%, and 97%, respectively. The sensitivity and specificity of galectin-3 immunodetection alone in discriminating benign from malignant thyroid lesions were more than 99% and 98% respectively, and the positive predictive value and diagnostic accuracy were 92% and 99%.
INTERPRETATION: The integration of galectin-3 immunostaining with conventional cytomorphological and clinical diagnostic procedures represents a sensitive and reliable diagnostic approach for preoperative identification of thyroid carcinomas. This test method improves the diagnostic accuracy of conventional cytology and provides the molecular basis for a new nosological assignation of the not yet classified thyroid neoplasms of indeterminate malignant behaviour.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425367     DOI: 10.1016/s0140-6736(00)04817-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  81 in total

Review 1.  Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate.

Authors:  R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 2.  The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia.

Authors:  Simon J Raphael
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 3.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 4.  Galectin genes: regulation of expression.

Authors:  Lorenzo Chiariotti; Paola Salvatore; Rodolfo Frunzio; Carmelo B Bruni
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

5.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.

Authors:  Janete M Cerutti; Rosana Delcelo; Marcelo João Amadei; Claudia Nakabashi; Rui M B Maciel; Bercedis Peterson; Jennifer Shoemaker; Gregory J Riggins
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 6.  Diagnostic role of galectin-3 in follicular thyroid tumors.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-03-04       Impact factor: 4.064

7.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors:  Rosa Marina Melillo; Maria Domenica Castellone; Valentina Guarino; Valentina De Falco; Anna Maria Cirafici; Giuliana Salvatore; Fiorina Caiazzo; Fulvio Basolo; Riccardo Giannini; Mogens Kruhoffer; Torben Orntoft; Alfredo Fusco; Massimo Santoro
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

8.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

Review 9.  How to define follicular thyroid carcinoma?

Authors:  Kurt Werner Schmid; Nadir Rashad Farid
Journal:  Virchows Arch       Date:  2006-02-28       Impact factor: 4.064

10.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Roberta DePompa; Enrico Saggiorato; Armando Bartolazzi; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-07-14       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.